- $398 million in first quarter global net product sales
- FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024
- On track to submit filing for pre-filled syringe (PFS) in second quarter 2024
- Management to host conference call today at 2:30 PM CET (8:30 AM ET)
The first quarter 2024 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website.
Dial-in numbers:
Please dial in 15 minutes prior to the live call.
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 800 715 9871
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.